Genotype 3 Infection: The Last Stand of Hepatitis C Virus.


Hepatitis C virus (HCV) represents a significant global disease burden, with an estimated 130-150 million people worldwide living with chronic HCV infection. Within the six major clinical HCV genotypes, genotype 3 represents 22-30% of all infection and is described as a unique entity with higher rates of steatosis, faster progression to cirrhosis, and higher rates of hepatocellular carcinoma. Hepatic steatosis in the setting of hepatitis C genotype 3 (HCV-3) is driven by viral influence on three major pathways: microsomal triglyceride transfer protein, sterol regulatory element-binding protein-1c, and peroxisome proliferator-associated receptor-α. Historically with direct-acting antivirals, the rates of cure for HCV-3 therapies lagged behind the other genotypes. As current therapies for HCV-3 continue to close this gap, it is important to be cognizant of common drug interactions such as acid-suppressing medication and amiodarone. In this review, we discuss the rates of steatosis in HCV-3, the mechanisms behind HCV-3-specific steatosis, and current and future therapies.

DOI: 10.1007/s40265-016-0685-x

4 Figures and Tables

Cite this paper

@article{Chan2017Genotype3I, title={Genotype 3 Infection: The Last Stand of Hepatitis C Virus.}, author={Austin W. Chan and Keyur Patel and Susanna Naggie}, journal={Drugs}, year={2017}, volume={77 2}, pages={131-144} }